These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 7657025)
1. Enhanced anticoagulant response to activated protein C in patients with IDDM. Krugluger W; Kopp HP; Schernthaner G; Hopmeier P Diabetes; 1995 Sep; 44(9):1033-7. PubMed ID: 7657025 [TBL] [Abstract][Full Text] [Related]
2. Activated-protein-C resistance in cancer patients. Green D; Maliekel K; Sushko E; Akhtar R; Soff GA Haemostasis; 1997; 27(3):112-8. PubMed ID: 9306127 [TBL] [Abstract][Full Text] [Related]
3. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Mahieu B; Jacobs N; Mahieu S; Naelaerts K; Vertessen F; Weyler J; Jacquemyn Y; Van der Planken M Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957 [TBL] [Abstract][Full Text] [Related]
4. Resistance to activated protein C: evaluation of three functional assays. Vasse M; Leduc O; Borg JY; Chrétien MH; Monconduit M Thromb Res; 1994 Oct; 76(1):47-59. PubMed ID: 7817360 [TBL] [Abstract][Full Text] [Related]
5. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method. Hoagland LE; Triplett DA; Peng F; Barna L Thromb Res; 1996 Sep; 83(5):363-73. PubMed ID: 8873345 [TBL] [Abstract][Full Text] [Related]
6. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation. De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766 [TBL] [Abstract][Full Text] [Related]
7. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Dahlbäck B; Carlsson M; Svensson PJ Proc Natl Acad Sci U S A; 1993 Feb; 90(3):1004-8. PubMed ID: 8430067 [TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C. De Mitrio V; Marino R; Cicinelli E; Galantino P; Di Bari L; Giannoccaro F; De Pergola G; Lapecorella M; Schonauer S; Schiraldi O Blood Coagul Fibrinolysis; 2000 Mar; 11(2):175-82. PubMed ID: 10759011 [TBL] [Abstract][Full Text] [Related]
9. Resistance to activated protein C as a basis for venous thrombosis. Svensson PJ; Dahlbäck B N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317 [TBL] [Abstract][Full Text] [Related]
10. A chromogenic assay for activated protein C resistance. Váradi K; Moritz B; Lang H; Bauer K; Preston E; Peake I; Rivard GE; Keil B; Schwarz HP Br J Haematol; 1995 Aug; 90(4):884-91. PubMed ID: 7669667 [TBL] [Abstract][Full Text] [Related]
11. A prothrombinase-based assay for detection of resistance to activated protein C. Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278 [TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. de Ronde H; Bertina RM Thromb Haemost; 1994 Dec; 72(6):880-6. PubMed ID: 7740458 [TBL] [Abstract][Full Text] [Related]
13. Lupus anticoagulant positivity in insulin dependent diabetic patients: an additional risk factor in the pathogenesis of diabetic retinopathy? Giusti C; Schiaffini R; Bosco D; Ciampalini P; Pantaleo A; Vingolo EM; Gargiulo P Br J Ophthalmol; 2000 May; 84(5):531-3. PubMed ID: 10781520 [TBL] [Abstract][Full Text] [Related]
14. Activated protein C sensitivity ratio in pregnant women at delivery. Mathonnet F; de Mazancourt P; Bastenaire B; Morot M; Benattar N; Beufé S; Borg JY; Giudicelli Y Br J Haematol; 1996 Jan; 92(1):244-6. PubMed ID: 8562404 [TBL] [Abstract][Full Text] [Related]
15. Activated protein C resistance in type I diabetes. Gruden G; Olivetti C; Cavallo-Perin P; Bazzan M; Stella S; Tamponi G; Pagano G Diabetes Care; 1997 Mar; 20(3):424-5. PubMed ID: 9051398 [TBL] [Abstract][Full Text] [Related]
16. Reference intervals and method optimization for variables reflecting hypocoagulatory and hypercoagulatory states in dogs using the STA Compact automated analyzer. Bauer N; Eralp O; Moritz A J Vet Diagn Invest; 2009 Nov; 21(6):803-14. PubMed ID: 19901280 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. Koedam JA; Meijers JC; Sixma JJ; Bouma BN J Clin Invest; 1988 Oct; 82(4):1236-43. PubMed ID: 2971673 [TBL] [Abstract][Full Text] [Related]
18. Endotoxaemia induces resistance to activated protein C in healthy humans. de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vlasuk GP; Rote WE; Levi M; Büller HR; Meijers JC Br J Haematol; 2006 Jul; 134(2):213-9. PubMed ID: 16846480 [TBL] [Abstract][Full Text] [Related]
19. Development of resistance to activated protein C during pregnancy. Cumming AM; Tait RC; Fildes S; Yoong A; Keeney S; Hay CR Br J Haematol; 1995 Jul; 90(3):725-7. PubMed ID: 7647019 [TBL] [Abstract][Full Text] [Related]
20. Species specificity of anticoagulant activity of activated human protein C: involvement of factor V as well as protein S. Katsuura Y; Mochizuki T; Tamura M; Hoshide S; Kiyoki M; Nakagaki T; Miyamoto S Thromb Res; 1996 Apr; 82(2):147-57. PubMed ID: 9163068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]